Company news

Lucid Diagnostics Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

March 18, 2025

Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test

March 13, 2025

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025

March 10, 2025

Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering

March 5, 2025

Lucid Diagnostics Announces $15.3 Million Registered Direct Offering

March 4, 2025

Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD

February 27, 2025

Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement

February 25, 2025

Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health

February 20, 2025

Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

February 5, 2025

Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume

January 12, 2025

Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

December 22, 2024

Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters

December 18, 2024

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication

December 10, 2024

Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones

December 2, 2024

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test

November 19, 2024

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

November 17, 2024

PAVmed Provides Business Update and Third Quarter 2024 Financial Results

November 13, 2024

Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results

November 12, 2024

Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

November 6, 2024

Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers

November 4, 2024

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024

October 29, 2024

Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test

October 14, 2024

Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit

October 8, 2024

Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024

October 7, 2024

Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players

September 30, 2024

American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test

September 23, 2024

PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements

September 15, 2024

Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress

September 9, 2024

Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health

September 2, 2024

Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer

August 19, 2024

The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer

August 12, 2024

PAVmed Provides Business Update and Second Quarter 2024 Financial Results

August 12, 2024

Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results

August 11, 2024

Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing Event

August 7, 2024

Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing

August 5, 2024

PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024

July 29, 2024

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024

July 28, 2024

Lucid Diagnostics Launches New Corporate Website

July 10, 2024

Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population

July 1, 2024

4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing

June 11, 2024

PAVmed Provides Business Update and First Quarter 2024 Financial Results

May 12, 2024

Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results

May 12, 2024

Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall

May 8, 2024

Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors

May 6, 2024

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024

May 1, 2024

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing

May 1, 2024

Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month

April 28, 2024

Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

April 7, 2024

Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results

March 24, 2024

Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population

March 20, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 11 decks. Every deck is listed under its year.